During a White House meeting with pharmaceutical representatives Tuesday, President Trump reiterated his pledge to bring down drug costs through streamlining approval processes, reducing regulations, and introducing more competition and bidding. The President also introduced a potentially radical approach to overhauling the U.S. Food and Drug Administration (FDA) by suggesting approving some drugs before they have been proven safe, a departure from FDA current practices. This came with the indication he would soon name a FDA commissioner that will also be streamlining the agency. Read more here.
Last Updated on May 12, 2020 by Aimed Alliance
